The pharmacologic blocking of IL-11 signaling in cancer contradicts to clinical application of recombinant human IL-11 (Oprelvekin) for stimulation of bone marrow to prevent chemotherapy-induced thrombocytopenia. Here, IL11 is linked to cancer.